SecurityKMR / Kinder Morgan, Inc. (49455U100)
President and CEOKEAN STEVEN J
IndustryNatural Gas Transmission
Institutional Owners0
Common Shares Outstanding2,206,828,970 shares (as of 2018-06-30)
Related 28336LBB4 / El Paso 6.7% Senior Notes 2/15/27
28336LBM0 / El Paso 6.875% Senior Notes 6/15/14
KMRFZ / Kinder Morgan Cum Pfd Ser A 144A
49455WAD8 / Kinder Morgan Finance Corp Ulc Guaranteed Notes 5.7% 01/05/16
49455WAF3 / Kinder Morgan Finance Corp Ulc Guaranteed Notes 6.4% 01/05/36
KMI / Kinder Morgan, Inc.
KMI.PRA / Kinder Morgan, Inc. 9.75% Dep Shares Series A Mandatory Convertible Preferred Stock
494553AC4 / Kinder Morgan Inc Senior Notes 5.15% 03/01/15
KMI.WS / Kinder Morgan, Inc. Warrants
482620AW1 / Kn Energy Inc Sr Db 7.25% 03/01/28
482620AX9 / Kn Energy Inc Sr Db 7.45% 03/01/98
CVB / Lehman ABS Corp Bkd Trust Certs 2002-06, 7.75% Kinder Morgan Debentures

Institutional Stock Ownership and Shareholders()

KMR / Kinder Morgan, Inc. Institutional Ownership

Kinder Morgan, Inc. (NYSE:KMR) has 0 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Largest shareholders include .
Kinder Morgan, Inc. (NYSE:KMR) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Prev Value
Current Value

Related Articles

REPH: Recro Pharma Analysis and Research Report

9h - Asif

Overview Recro Pharma is a specialty pharmaceutical company that operates through two business divisions: an Acute Care division and a revenue-generating CDMO division. Each of these divisions are deemed to be reportable segments for financial reporting purposes. The company's Acute Care segment is primarily focused on developing and commercializing innovative products for hospital and related acute care settings. The company's lead product candidate is a proprietary injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials for the management of moderate to severe pain, consisting of two pivotal efficacy trials and a large double-blind Phase III safety trial, as well as other safety studies. Overall, the total new drug application, or NDA, program included over 1,400 patients. In late July 2017, the company submitted a NDA to the U.S. Food and Drug Administration, or FDA, for IV meloxicam...

ACHN: Achillion Pharmaceuticals Analysis and Research Report

9h - Asif

Overview Achillion Pharmaceuticals is a clinical-stage biopharmaceutical company focused on advancing its oral factor D inhibitors into late-stage development and commercialization. Each of the drug candidates in its oral factor D portfolio was discovered in its laboratories and is wholly owned by it. Achillion Pharmaceuticals is focusing its drug development activities on alternative pathway-mediated, rare diseases where there are no approved therapies or where existing therapies are inadequate for patients. To advance its investigational drugs into phase III and commercialization, the company plan to work closely with key stakeholders including patients, payors, regulators and healthcare professionals. The company's first-generation factor D inhibitor, ACH-4471, has demonstrated preliminary clinical proof-of-concept in patients with C3 glomerulopathy, or C3G, a disease affecting the kidney, and paroxysmal nocturnal hemoglobinuria, or PNH, a blood disorder, and has advanced...

BTE: Baytex Energy Trust Analysis and Research Report

10h - Asif

General Baytex Energy Corp. was incorporated on October 22, 2010 pursuant to the provisions of the ABCA. Baytex is the successor to the business of Baytex Energy Trust, which was transitioned to Baytex on December 31, 2010. Inter-Corporate Relationships The following table provides the name, the percentage of voting securities owned by it and the jurisdiction of incorporation, continuance, formation or organization of its material subsidiaries either, direct and indirect, as at the date hereof. ||Percentage of voting securities (directly or indirectly)|Jurisdiction of Incorporation/Formation| | ------------ | ------------: | :------------: | |Baytex Energy Ltd.|100%|Alberta| |Baytex Energy USA, Inc.|100%|Delaware| |Baytex Energy Partnership|100%|Alberta| Organizational Structure The following simplified diagram shows the inter-corporate relationships among it and its material subsidiaries as of the date hereof. <img src="

Related News Stories

TransCanada's Keystone XL Pipeline Faces Another Legal Snag

1h zacks
A cloud of uncertainty seems to be hovering around TransCanada Corporation’s (TRP - Free Report) Keystone XL pipeline project yet again. After facing delays for near about a decade, the pipeline finally received a regulatory approval from Nebraska commissioners late last year, albeit on an alternative route to the one proposed by the company. However, the pipeline has been hit by a fresh controversy again, as rerouting of the pipeline has subjected it to new legal investigation. (3-0)

'People on the path' aims to show not everyone is pro-pipeline, group says

A non-profit group is using art to send a message to politicians and the oil and gas industry that not everyone supports more pipelines in Alberta and Canada. (1-0)

Kinder Morgan's Dividend Isn't Fairly Valued

12h seekingalpha
A dividend discount model implies multiple turns of upside for the stock as management is looking to 25% increases post-2020. (1-0)

Kinder Morgan: A Still Growing Giant

21h seekingalpha
Kinder Morgan is the largest pipeline company in North America, which gives it the ability to undertake very ambitious projects. (1-0)

No Encore, Deck Still Stacked For Midstream

2018-08-19 seekingalpha
The string of successive positive weeks for midstream ended this week. Midstream stocks were down roughly 1% across MLP and midstream indexes. Canadian Midstream stocks outperformed for the first time in a while. Utilities had a very strong week and the S&P was slightly positive. Oil prices continue to languish, now down 7 straight weeks, while natural gas prices continue to hold firm. (16-0)

CUSIP: 49455U100